208 related articles for article (PubMed ID: 30474428)
1. c-Met kinase inhibitors: an update patent review (2014-2017).
Zhang QW; Ye ZD; Shi L
Expert Opin Ther Pat; 2019 Jan; 29(1):25-41. PubMed ID: 30474428
[TBL] [Abstract][Full Text] [Related]
2. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
4. Recent Patents on the Development of c-Met Kinase Inhibitors.
Xu X; Yao L
Recent Pat Anticancer Drug Discov; 2020; 15(3):228-238. PubMed ID: 32603284
[TBL] [Abstract][Full Text] [Related]
5. Optimization techniques for novel c-Met kinase inhibitors.
Sun ZG; Yang YA; Zhang ZG; Zhu HL
Expert Opin Drug Discov; 2019 Jan; 14(1):59-69. PubMed ID: 30518273
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
7. C-MET inhibitors for advanced non-small cell lung cancer.
Pasquini G; Giaccone G
Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
[TBL] [Abstract][Full Text] [Related]
8. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present).
Chu C; Rao Z; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Mar; 32(3):279-298. PubMed ID: 34791961
[TBL] [Abstract][Full Text] [Related]
9. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
10. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Dussault I; Bellon SF
Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
12. c-Met inhibitors with different binding modes: two is better than one.
Dussault I; Bellon SF
Cell Cycle; 2008 May; 7(9):1157-60. PubMed ID: 18418040
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
14. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
15. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
17. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
Roskoski R
Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
[TBL] [Abstract][Full Text] [Related]
18. A patent review of RAF kinase inhibitors (2010-2018).
Man RJ; Zhang YL; Jiang AQ; Zhu HL
Expert Opin Ther Pat; 2019 Sep; 29(9):675-688. PubMed ID: 31370713
[No Abstract] [Full Text] [Related]
19. Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present).
Lv PC; Wang ZC; Zhu HL
Curr Med Chem; 2017; 24(1):57-64. PubMed ID: 27804876
[TBL] [Abstract][Full Text] [Related]
20. The multiple paths towards MET receptor addiction in cancer.
Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]